La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Bonesupport Holding Gestion

Gestion contrôle des critères 3/4

Le PDG Bonesupport Holding's est Emil Billbäck, nommé en Mar2018, a un mandat de 6.42 ans. La rémunération annuelle totale est SEK 15.18M, composée du salaire de 41.7% et des bonus 58.3%, y compris les actions et options de la société. détient directement 0.6% des actions de la société, d'une valeur de SEK 108.13M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.8 ans et 7.6 ans.

Informations clés

Emil Billbäck

Directeur général

SEK 15.2m

Rémunération totale

Pourcentage du salaire du PDG	41.7%
Durée du mandat du directeur général	6.4yrs
Propriété du PDG	0.6%
Durée moyenne d'occupation des postes de direction	4.8yrs
Durée moyenne du mandat des membres du conseil d'administration	7.6yrs

Mises à jour récentes de la gestion

Recent updates

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

Mar 16

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Nov 06

Bonesupport Holding AB (publ)'s (STO:BONEX) Path To Profitability

Mar 31

Insider Buying: The Bonesupport Holding AB (publ) (STO:BONEX) Chief Executive Officer Just Bought 4.0% More Shares

Mar 04

One Bonesupport Holding AB (publ) (STO:BONEX) Analyst Just Cut Their EPS Forecasts

Mar 02

What Kind Of Investors Own Most Of Bonesupport Holding AB (publ) (STO:BONEX)?

Feb 28

Analyse de la rémunération des PDG

Comment la rémunération de Emil Billbäck a-t-elle évolué par rapport aux bénéfices de Bonesupport Holding?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	SEK 289m
Mar 31 2024	n/a	n/a	SEK 267m
Dec 31 2023	SEK 15m	SEK 6m	SEK 245m
Sep 30 2023	n/a	n/a	SEK 214m
Jun 30 2023	n/a	n/a	-SEK 30m
Mar 31 2023	n/a	n/a	-SEK 51m
Dec 31 2022	SEK 18m	SEK 5m	-SEK 68m
Sep 30 2022	n/a	n/a	-SEK 72m
Jun 30 2022	n/a	n/a	-SEK 71m
Mar 31 2022	n/a	n/a	-SEK 82m
Dec 31 2021	SEK 6m	SEK 4m	-SEK 86m
Sep 30 2021	n/a	n/a	-SEK 88m
Jun 30 2021	n/a	n/a	-SEK 96m
Mar 31 2021	n/a	n/a	-SEK 92m
Dec 31 2020	SEK 11m	SEK 6m	-SEK 101m
Sep 30 2020	n/a	n/a	-SEK 115m
Jun 30 2020	n/a	n/a	-SEK 127m
Mar 31 2020	n/a	n/a	-SEK 151m
Dec 31 2019	SEK 8m	SEK 5m	-SEK 161m
Sep 30 2019	n/a	n/a	-SEK 166m
Jun 30 2019	n/a	n/a	-SEK 191m
Mar 31 2019	n/a	n/a	-SEK 182m
Dec 31 2018	SEK 6m	SEK 4m	-SEK 176m

Rémunération vs marché: La rémunération totale de Emil ($USD 1.49M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Swedish ($USD 778.42K ).

Rémunération et revenus: La rémunération de Emil a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Emil Billbäck (54 yo)

6.4yrs

Titularisation

SEK 15,176,000

Compensation

Mr. Emil Billbäck serves as Director of Intervacc AB (publ) since May 15, 2024. He has been Chief Executive Officer at BONESUPPORT HOLDING AB (publ) since March 01, 2018. Mr. Billbäck is the Chief Executiv...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Emil Billbäck	Chief Executive Officer	6.4yrs	SEK 15.18m	0.60% SEK 108.1m
Håkan Johansson	Chief Financial Officer	5.8yrs	SEK 248.00k	0.084% SEK 15.2m
Michael Mortensen	Executive Vice President of Global R&D and Operations	2.7yrs	pas de données	0% SEK 0
Annelie Vikner	Executive Vice President of Global Marketing	1.6yrs	pas de données	0.022% SEK 4.0m
Helena Brandt	Executive Vice President of Human Resources	6.8yrs	pas de données	0.015% SEK 2.8m
Michael Diefenbeck	Executive VP of Medical & Clinical Affairs and Chief Medical Officer	7.3yrs	pas de données	0.099% SEK 18.1m
Fergus MacLeod	GM & Executive VP of Commercial Operations of EUROW	4.8yrs	pas de données	0.036% SEK 6.6m
Michael Roth	GM & Executive VP of Commercial Operations of North America	4.2yrs	pas de données	0.030% SEK 5.5m
Anna Stegmark	Executive Vice President of Quality Management & Regulatory Affairs	less than a year	pas de données	pas de données

4.8yrs

Durée moyenne de l'emploi

54yo

Âge moyen

Gestion expérimentée: L'équipe de direction de BONEX est considérée comme expérimentée (ancienneté moyenne 4.8 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Björn Odlander	Director	14.6yrs	SEK 302.00k	pas de données
Lennart Johansson	Independent Chairman of the Board	7.6yrs	SEK 2.94m	0.25% SEK 46.2m
Sven Bjorklund	Independent Director	7.7yrs	SEK 253.00k	pas de données
Christine Rankin	Independent Director	2.3yrs	SEK 756.00k	0.0036% SEK 645.1k
Mary O'Connor	Independent Director	2.3yrs	SEK 515.00k	0.038% SEK 6.9m

7.6yrs

Durée moyenne de l'emploi

67yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de BONEX sont considérés comme expérimentés (ancienneté moyenne 7.6 ans).

Bonesupport Holding Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Chief Executive Officer recently sold kr18m worth of stock

Bonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024

Key Executive recently sold kr3.6m worth of stock

Insider recently sold kr478k worth of stock

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Independent Director recently bought kr1.0m worth of stock

Recent updates

Now 22% undervalued

Price target increased by 8.6% to kr323

Consensus EPS estimates fall by 12%, revenue upgraded

Chief Executive Officer recently sold kr18m worth of stock

Second quarter 2024 earnings released: EPS: kr0.42 (vs kr0.08 in 2Q 2023)

Consensus EPS estimates fall by 14%

Bonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024

Key Executive recently sold kr3.6m worth of stock

Insider recently sold kr478k worth of stock

First quarter 2024 earnings released

Full year 2023 earnings: EPS exceeds analyst expectations

Price target increased by 14% to kr293

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 24%, revenue upgraded

Independent Director recently bought kr1.0m worth of stock

Bonesupport Holding AB Provides Sales Guidance for the Year 2024

Price target increased by 11% to kr179

Third quarter 2023 earnings released

Bonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone Infection

Independent Director recently bought kr1.1m worth of stock

Insider recently bought kr426k worth of stock

Second quarter 2023 earnings released: EPS: kr0.08 (vs kr0.25 loss in 2Q 2022)

BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open Fractures

Insider recently sold kr701k worth of stock

Forecast breakeven date moved forward to 2023

Chief Executive Officer recently sold kr15m worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold kr1.4m worth of stock

Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)

Price target increased by 17% to kr142

Bonesupport Holding AB (publ), Annual General Meeting, Nov 21, 2023

Director recently bought kr203k worth of stock

No independent directors

Bonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings released

No longer forecast to breakeven

Bonesupport's CERAMENT G Used in First U.S. Patient Cases

Forecast to breakeven in 2023

An unknown buyer acquired unknown minority stakes in Bonesupport Holding AB (publ) (OM:BONEX) from Helena Brandt for SEK 0.84 million.

Bonesupport Holding AB (publ) Announces Publication of Mid- to Long-Term Data Confirming the Sustained Clinical Effectiveness of CERAMENT G

Consensus forecasts updated

Second quarter 2022 earnings released: kr0.25 loss per share (vs kr0.42 loss in 2Q 2021)

Insider recently bought kr101k worth of stock

Forecast breakeven date moved forward to 2023

Price target increased to kr91.00

BONESUPPORT Receives Market Authorization for CERAMENT G in the US

Forecast breakeven date pushed back to 2024

Chairman of the Board recently bought kr1.2m worth of stock

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Bonesupport Holding AB (publ) to Report Fiscal Year 2021 Final Results on Apr 13, 2022

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

BONESUPPORT(TM) Announces Delays Within FDA Postpones CERAMENT G De Novo Decision

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Insider recently bought kr182k worth of stock

Third quarter 2021 earnings released

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Bonesupport Announces Supplementary US Denovo Application Submitted

Chief Executive Officer recently bought kr343k worth of stock

Price target decreased to kr65.00

Bonesupport Announces Study Results for its Investigational Device Exemption(IDE) Study, Fortify

Chief Financial Officer recently bought kr87k worth of stock

Insider recently bought kr401k worth of stock

Chairman of the board recently bought kr1.6m worth of stock